RALEIGH, N.C., April 21, 2011 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that an abstract has been accepted for presentation at the annual American Diabetes Association ("ADA") Scientific Sessions to be held in San Diego, CA, June 24 - 28, 2011. The poster presentation will provide details on the company's lead once-a-day, oral diabetes drug candidate DB959 for which a Phase 1b clinical trial initiated Q1 2011.
